Healios K.K. (4593.T)
JPY 181.0
(1.69%)
JPY 181.0
(1.69%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.28 Billion JPY | 5.96% |
| 2022 | 10.65 Billion JPY | -30.5% |
| 2021 | 15.32 Billion JPY | 0.04% |
| 2020 | 15.32 Billion JPY | 26.35% |
| 2019 | 12.12 Billion JPY | 188.83% |
| 2018 | 4.19 Billion JPY | 18.83% |
| 2017 | 3.53 Billion JPY | 11.07% |
| 2016 | 3.18 Billion JPY | 186.47% |
| 2015 | 1.11 Billion JPY | 118.93% |
| 2014 | 507.11 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 12.76 Billion JPY | 13.13% |
| 2024 Q2 | 14.54 Billion JPY | 13.93% |
| 2023 Q2 | 11.43 Billion JPY | 0.95% |
| 2023 Q4 | 11.28 Billion JPY | -8.62% |
| 2023 FY | 11.28 Billion JPY | 5.96% |
| 2023 Q3 | 12.35 Billion JPY | 8.02% |
| 2023 Q1 | 11.32 Billion JPY | 6.34% |
| 2022 Q3 | 10.32 Billion JPY | -36.64% |
| 2022 Q2 | 16.29 Billion JPY | 3.73% |
| 2022 Q1 | 15.7 Billion JPY | 2.5% |
| 2022 FY | 10.65 Billion JPY | -30.5% |
| 2022 Q4 | 10.65 Billion JPY | 3.17% |
| 2021 Q1 | 15.05 Billion JPY | -1.76% |
| 2021 FY | 15.32 Billion JPY | 0.04% |
| 2021 Q4 | 15.32 Billion JPY | -1.17% |
| 2021 Q2 | 14.5 Billion JPY | -3.64% |
| 2021 Q3 | 15.5 Billion JPY | 6.93% |
| 2020 Q1 | 15.17 Billion JPY | 25.16% |
| 2020 Q2 | 14.65 Billion JPY | -3.41% |
| 2020 Q3 | 14.57 Billion JPY | -0.55% |
| 2020 Q4 | 15.32 Billion JPY | 5.09% |
| 2020 FY | 15.32 Billion JPY | 26.35% |
| 2019 Q3 | 12.12 Billion JPY | 269.04% |
| 2019 FY | 12.12 Billion JPY | 188.83% |
| 2019 Q2 | 3.28 Billion JPY | -8.14% |
| 2019 Q1 | 3.57 Billion JPY | -14.82% |
| 2019 Q4 | 12.12 Billion JPY | 0.02% |
| 2018 FY | 4.19 Billion JPY | 18.83% |
| 2018 Q2 | 5.3 Billion JPY | 67.95% |
| 2018 Q4 | 4.19 Billion JPY | -15.16% |
| 2018 Q1 | 3.15 Billion JPY | -10.61% |
| 2018 Q3 | 4.94 Billion JPY | -6.71% |
| 2017 Q2 | 3.55 Billion JPY | 16.83% |
| 2017 Q3 | 3.75 Billion JPY | 5.58% |
| 2017 Q1 | 3.04 Billion JPY | -4.31% |
| 2017 Q4 | 3.53 Billion JPY | -5.9% |
| 2017 FY | 3.53 Billion JPY | 11.07% |
| 2016 FY | 3.18 Billion JPY | 186.47% |
| 2016 Q2 | 3.66 Billion JPY | 7.37% |
| 2016 Q1 | 3.41 Billion JPY | 207.3% |
| 2016 Q4 | 3.18 Billion JPY | -9.25% |
| 2016 Q3 | 3.5 Billion JPY | -4.33% |
| 2015 Q4 | 1.11 Billion JPY | 5.57% |
| 2015 Q2 | 1.14 Billion JPY | 0.0% |
| 2015 FY | 1.11 Billion JPY | 118.93% |
| 2015 Q3 | 1.05 Billion JPY | -8.24% |
| 2014 FY | 507.11 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | -247.59% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -17698.174% |
| GNI Group Ltd. | 26.34 Billion JPY | 57.155% |
| Linical Co., Ltd. | 10.3 Billion JPY | -9.521% |
| Trans Genic Inc. | 3.81 Billion JPY | -196.023% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -1812.22% |
| Soiken Holdings Inc. | 697.02 Million JPY | -1519.172% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -273.616% |
| AnGes, Inc. | 2.78 Billion JPY | -304.608% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -2097.4% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 87.514% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -3094.715% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -584.046% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -2289.305% |
| CanBas Co., Ltd. | 91.98 Million JPY | -12168.992% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -931.999% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -1293.626% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -1800.861% |
| Kidswell Bio Corporation | 4.25 Billion JPY | -165.299% |
| PeptiDream Inc. | 29.11 Billion JPY | 61.236% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -1892.233% |
| Ribomic Inc. | 155.8 Million JPY | -7143.484% |
| SanBio Company Limited | 2.25 Billion JPY | -400.512% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -4391.601% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -2958.537% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -4573.35% |
| StemRIM | 187 Million JPY | -5935.294% |
| CellSource Co., Ltd. | 677.73 Million JPY | -1565.243% |
| FunPep Company Limited | 189.32 Million JPY | -5861.209% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -1790.595% |
| Stella Pharma Corporation | 1.44 Billion JPY | -681.79% |
| TMS Co., Ltd. | 97.68 Million JPY | -11452.99% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -12235.235% |
| Cuorips Inc. | 200.96 Million JPY | -5516.015% |
| K Pharma,Inc. | 209.13 Million JPY | -5296.54% |
| Takara Bio Inc. | 11.42 Billion JPY | 1.173% |
| ReproCELL Incorporated | 741.03 Million JPY | -1423.011% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -1129.796% |
| StemCell Institute Inc. | 3.85 Billion JPY | -193.108% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -1142.362% |
| CellSeed Inc. | 301.04 Million JPY | -3648.916% |